1. Home
  2. REPL vs EEX Comparison

REPL vs EEX Comparison

Compare REPL & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • EEX
  • Stock Information
  • Founded
  • REPL 2015
  • EEX 2013
  • Country
  • REPL United States
  • EEX United States
  • Employees
  • REPL N/A
  • EEX N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • EEX Advertising
  • Sector
  • REPL Health Care
  • EEX Consumer Discretionary
  • Exchange
  • REPL Nasdaq
  • EEX Nasdaq
  • Market Cap
  • REPL 897.3M
  • EEX 982.4M
  • IPO Year
  • REPL 2018
  • EEX 2017
  • Fundamental
  • Price
  • REPL $12.49
  • EEX $4.80
  • Analyst Decision
  • REPL Strong Buy
  • EEX Strong Buy
  • Analyst Count
  • REPL 6
  • EEX 2
  • Target Price
  • REPL $17.50
  • EEX $7.90
  • AVG Volume (30 Days)
  • REPL 1.3M
  • EEX 228.8K
  • Earning Date
  • REPL 02-06-2025
  • EEX 10-30-2024
  • Dividend Yield
  • REPL N/A
  • EEX 1.25%
  • EPS Growth
  • REPL N/A
  • EEX N/A
  • EPS
  • REPL N/A
  • EEX N/A
  • Revenue
  • REPL N/A
  • EEX $393,500,000.00
  • Revenue This Year
  • REPL N/A
  • EEX $5.54
  • Revenue Next Year
  • REPL $300.41
  • EEX $7.75
  • P/E Ratio
  • REPL N/A
  • EEX N/A
  • Revenue Growth
  • REPL N/A
  • EEX 4.96
  • 52 Week Low
  • REPL $4.92
  • EEX $3.92
  • 52 Week High
  • REPL $17.00
  • EEX $7.05
  • Technical
  • Relative Strength Index (RSI)
  • REPL 50.53
  • EEX 52.44
  • Support Level
  • REPL $11.19
  • EEX $4.60
  • Resistance Level
  • REPL $12.79
  • EEX $4.87
  • Average True Range (ATR)
  • REPL 0.70
  • EEX 0.17
  • MACD
  • REPL -0.14
  • EEX -0.03
  • Stochastic Oscillator
  • REPL 52.21
  • EEX 39.22

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

About EEX Emerald Holding Inc.

Emerald Holding Inc is an operator of B2B trade shows in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry, Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. Majority of the revenue for the company is generated from its Connections segment.

Share on Social Networks: